Wall Street Brokers Increase Cannabis Stock Allocations
Financial advisors expand cannabis exposure as institutional adoption accelerates across major brokerage platforms.
Wall Street brokerage firms are expanding their cannabis stock offerings and increasing allocations to marijuana-related securities, marking a shift in institutional acceptance of the sector. Major wirehouses now provide clients access to multi-state operators like Curaleaf (CURLF) and Trulieve (TCNNF), alongside ancillary plays such as Innovative Industrial Properties (IIPR) and Scotts Miracle-Gro (SMG).
The trend reflects growing institutional comfort with cannabis investments as the sector matures and regulatory clarity improves. Brokers cite client demand and the industry's $30 billion annual revenue as key drivers for expanded coverage. Traditional wealth management platforms that previously avoided cannabis exposure now offer curated portfolios including both direct operators and cannabis-adjacent businesses.
Institutional adoption faces headwinds from federal prohibition, which creates compliance complexities for regulated financial institutions. Many brokers limit exposure to Canadian licensed producers like Canopy Growth (CGC) and Tilray (TLRY) that trade on major U.S. exchanges, while restricting access to over-the-counter MSO securities that carry additional regulatory risk.
The sector's volatility remains a concern for risk-averse institutional investors, with cannabis stocks experiencing dramatic swings based on regulatory developments and earnings volatility. However, brokers increasingly view selective cannabis exposure as essential for comprehensive portfolio construction, particularly as state-level legalization accelerates and federal reform discussions gain momentum.
This institutional embrace could provide crucial capital access for cannabis companies struggling with traditional banking restrictions. As more brokers integrate cannabis into standard investment offerings, the sector moves closer to mainstream financial acceptance, potentially reducing the regulatory risk premium that has historically weighed on valuations across the space.